A 34-year-old healthy woman presented with a 15-month history of persistent, nonhealing vulvar ulcerations due to herpes simplex virus (HSV) type 2. Extensive dermatologic workup and serial skin biopsies failed to reveal an underlying vulvar dermatosis or autoimmune bullous disorder. Virologic studies revealed resistance to acyclovir in vitro due to deficiency in thymidine kinase activity. Serum antibody to human immunodeficiency virus was negative on two occasions, separated by 1 year. Immunologic evaluation showed normal HSV-specific proliferative and CD8 cytotoxic T lymphocyte responses as well as normal NK cell function. Vulvar lesions failed to heal in association with trials of topical trifluorothymidine and oral valacyclovir but resolved completely with the application of 1% foscarnet cream. No recurrence of HSV has been observed in 24 months of followup to date.
Clinically significant acyclovir-resistant herpes simplex vinisms of action: It can bind to and inactivate the viral DNA polymerase directly, or it can be incorporated into and terminate rus (HSV) infections were relatively rare until the onset of the AIDS epidemic in the mid-1980s [1, 2] . Acyclovir-resistant new viral DNA synthesis [6, 7] . Resistance to acyclovir may result from mutations in the viral genes encoding TK or DNA HSV isolates have been identified in immunocompetent patients, although drug resistance has not generally correlated polymerase [8 -12] . Changes in the TK gene have led to viruses that are either deficient, altered, or low-activity phenotypes. with clinical disease [3] . In fact, animal models have shown attenuated virulence of certain acyclovir-resistant HSV isolates, Altered DNA polymerase mutants have been identified in clinical isolates of HSV recovered from immunocompromised pawith reduced mucocutaneous pathogenicity and decreased recurrence of latent disease [4, 5] . tients but are rare [13 -15] . Clinically significant acyclovir-resistant HSV disease has Acyclovir is a selective and specific inhibitor of HSV replication because its antiviral activity depends on two virally enpreviously been limited to severely immunocompromised patients, especially AIDS patients [16] . In 1993, however, Kost coded enzymes, thymidine kinase (TK) and DNA polymerase. Once acyclovir has diffused into the cell, the viral TK converts et al. [17] described an immunocompetent, human immunodeficiency virus (HIV) -negative man with a history of unsafe it to acyclovir monophosphate, and cellular enzymes add two more phosphates to generate the active antiviral metabolite, intercourse with HIV-positive men and frequently recurring genital herpes that was resistant to treatment with high-dose acyclovir triphosphate. Acyclovir triphosphate has two mechaoral acyclovir. Virologic characterization of this patient's isolate revealed acyclovir-resistant HSV-2 with a TK-altered phenotype.
We report the first case of clinically significant acyclovir-pruritic vulvar erosions and an adherent, mucoid vulvovaginal disBecause of the possibility of underlying lichen planus, lowpotency topical steroids (desonide 0.05%) were added to the regicharge for the preceding 15 months. Prior viral cultures from the vulvar area through June 1993 were reportedly positive for HSVmen in August 1993, with significant reduction in vulvar pain and burning. Over the ensuing 3 months, mid-to high-potency topical 2, and a skin biopsy in April 1992 showed intense inflammation and multinucleated cells indicative of HSV infection.
steroids (mometasone furoate, 0.1%, and clobetasol propionate, 0.05%, ointments) were prescribed for possible erosive vulvar liPhysical examination revealed well-demarcated, tender, erythematous erosions on the labia minora and clitoral hood. A graychen planus. A trial of oral prednisone was started in early December 1993, and within 2 weeks, the patient's vulvar erosions were white pseudomembranous exudate was present over several erosions, and scant clear vaginal discharge was noted. The oropharynx nearly reepithelialized while receiving systemic steroids and highdose oral acyclovir (800 mg five times daily). However, in January showed no erosions, aphthous ulcers, or evidence of lichen planus. Skin examination was otherwise unremarkable.
1994, her symptoms worsened despite continuation of this regimen and after a gradual prednisone taper. Viral cultures done every 2 The patient recalled the first symptomatic outbreak of genital herpes in July 1990, following an episode of unprotected sexual weeks were positive for HSV-2, vulvar erosions showed poor healing, and the thick, pseudomembranous vulvovaginal discharge reintercourse. Initial outbreaks occurred every 4-5 weeks thereafter and healed in response to oral acyclovir (e.g., 200 mg five times appeared. In vitro resistance to acyclovir was again documented in 2 vulvar HSV-2 isolates from January 1994 (14849 and 14848), daily). The patient reported no lesions when not receiving treatment from August 1991 to December 1991. However, in early obtained before cessation of low-dose systemic steroids and oral acyclovir (table 1) . Repeat vulvar biopsy showed a similar li-1992, she noted abrupt worsening of her genital herpes, with prolonged healing of vulvar erosions and new lesions occurring on a chenoid infiltrate and ulceration without specific herpesvirus findings. weekly basis. Over the next 12-15 months, the patient was treated with intermittent doses of acyclovir ranging from 200 mg five Because of lack of effect, oral acyclovir was discontinued in early February 1994, and the prednisone taper continued. An HSV times daily to 600 mg five times daily, with continued slow healing of vulvar lesions and frequent recurrences both while receiving isolate collected in mid-February while the patient was receiving oral prednisone alone at 20 mg every other day (14847) again and while not receiving acyclovir therapy. Although individual lesions eventually healed over several weeks, the patient developed showed acyclovir resistance. A trial of trifluorothymidine (TFT; 1% ophthalmic solution) was initiated in late February 1994 and recurrent vulvar erosions at different sites on a continual basis beginning in April 1992. A diagram of the patient's clinical course continued after oral prednisone was stopped in March 1994. TFT mixed with bacitracin zinc-polymyxin B sulfate and Aquaphor of therapy is shown in figure 1 .
Serum antibodies to HIV were absent on two occasions, in 1992 (Beiersdorf, Norwalk, CT) ointments was applied thrice daily for 2 weeks without healing of vulvar erosions. Serial alterations in and 1993. Further immunologic workup was done in July 1993 to rule out occult immunodeficiency. A quantitative immunoglobulin therapy over the total 8-week course included the addition of topical steroid therapy, application of TFT 1% solution alone, and the assay revealed normal IgG, IgA, and IgM levels. The percentage of T and B lymphocyte subsets (CD4, CD8, CD4:CD8 ratio, and use of topical TFT mixed with mupirocin ointment, all without clinical or virologic effect. Topical TFT therapy was discontinued CD20) were normal, as were absolute lymphocyte counts. A fluorescent anti-nuclear antibody titer was positive ( §1:640) in a in April 1994. In May 1994, repeat vulvar biopsy while the patient was receivspeckled pattern. Further tests for collagen vascular disease showed negative antibodies to double-stranded DNA, extractable ing no topical or systemic therapy showed histologic changes characteristic of herpetic infection, including ulceration, adjacent multinuclear antigens, and to SS-A (Ro) and SS-B (La), effectively excluding systemic lupus erythematosus, mixed connective tissue nucleated giant cell formation, and intranuclear viral inclusion bodies within epithelial cells. Direct immunofluorescence testing disease, Sjogren's syndrome, or subacute cutaneous lupus erythematosus.
on the biopsy tissue was again negative for autoimmune bullous disease. An HSV-2 vulvar isolate (15923) collected in June 1993, before any antiinflammatory agents were introduced or antiviral medicaIn September 1994, a trial of oral valacyclovir was initiated (1 g four times daily for 6 weeks, followed by 2 g four times daily tions restarted, was found to be resistant to acyclovir in vitro (ID 50 , 17.5 mg/mL) (table 1). Repeat vulvar biopsy in July 1993 showed for 8 weeks), without significant clinical improvement or conversion of viral cultures to negative. Peak steady-state plasma levels ulceration with a lichenoid lymphocytic infiltrate and overlying lichen simplex chronicus. No specific viral changes were noted in of acyclovir were found to be high while the patient was receiving both the lower and higher doses of valacyclovir (9.6 and 18.5 mg/ the biopsy specimen, and direct immunofluorescence testing was negative for autoimmune bullous diseases, such as pemphigus vulmL, respectively). Valacyclovir was discontinued in January 1995.
Repeat antiviral susceptibility testing confirmed acyclovir resisgaris, cicatricial or bullous pemphigoid, or bullous lupus erythematosus. The biopsy specimen suggested a possible diagnosis of litance and susceptibility to foscarnet, both before and after valacyclovir cessation (isolates 15583 and 15582, respectively; table chen planus, although the lack of oral mucosal findings did not support a diagnosis of erosive vulvar lichen planus.
1). Therapy with topical foscarnet cream (1%) was initiated in June Beginning in July 1993, the patient received oral acyclovir (800 mg five times daily), with topical application of mupirocin oint-1995. The cream was applied with a gloved hand five times daily, with dramatic reduction in chronic pain and burning within the ment to vulvar erosions thrice daily. The patient noted moderate improvement in vulvar pain and discharge while receiving the first 24 h, and marked reepithelialization of all erosions evident within 5 days. Complete reepithelialization was noted at 2 weeks. above regimen, and vulvar pruritus decreased with oral antihistamines.
Viral cultures were negative for HSV-2 at 2 weeks and 4 weeks, / 9d41$$mr21 01-21-98 18:28:24 jinfa UC: J Infect and no clinical recurrence was evident at weeks 6 and 10 of the that of controls following a 1-week exposure of the fixed monolayers to Kodak X-Omat film, and the isolates were classified as foscarnet trial. According to the patient, a small vulvar erosion recurred after 9 weeks (September 1995) but resolved completely TK-positive, TK-deficient, TK-altered, or TK-low activity phenotypes [20] . Three of the original isolates (14849, 14848, and 15582) after four applications of foscarnet cream over a 24-h period. The patient has remained free of vulvar pain and erosions since that were mixed populations containing 2%-10% TK-positive virus (table 1). All of the HSV isolates were acyclovir-resistant in vitro time.
and may indicate the limits of our assay methods; however, the 2 chosen for further animal study (14847 and 14848) were 98%-100% TK-deficient populations. Virus isolates were plaque-puri-
Materials and Methods
fied to homogeneity through three rounds of plaque purification, An Investigational New Drug (IND) application was approved and typing was verified by type-specific polymerase chain reaction by the US Food and Drug Administration for the use of vala-(PCR) primers. Plasma acyclovir levels were measured by scintilcyclovir (IND 46,008) and foscarnet cream (IND 47,844). Oral lation proximity RIA [21] . valacyclovir pills were supplied by Glaxo Wellcome (Research The TK phenotypes of these isolates were further characterized Triangle Park, NC), and foscarnet cream by Astra Pharmaceuticals by the ability of the viral TK to phosphorylate thymidine and (Westborough, MA).
were determined on crude extracts of TK-deficient 143B cells as In vitro susceptibility testing and phenotypic analysis. Antividescribed elsewhere [20] . After subtracting out the cells' backral susceptibility testing to acyclovir and foscarnet was done by ground activity, acyclovir-resistant isolates that had õ1% wild use of the plaque reduction assay in Vero cells, as previously type activity were classified as TK-deficient, isolates between 1% described [18] . TK phenotype was characterized by plaque autoraand 15% were TK-low activity types, and isolates that had 15%-diography as described by Martin et al. [19] . Virus plaques in 100% activity were classified as TK-altered. TK-altered phenoeither Vero cells (ATCC CCL 81) or 143B cells (ATCC CRL types are distinguished from TK-positive phenotypes by their in-8303, a TK-deficient human osteosarcoma cell line) were labeled ability to phosphorylate acyclovir in the EIAs [8] . NOTE. Susceptibility testing was done by plaque reduction assay. TK, thymidine kinase. Dates are given as month/day/year. * ID 50 §2 mg/mL defines resistance to acyclovir; ID 50 §100 mg/mL defines resistance to foscarnet. † Phenotypic characterization was done by plaque autoradiography. These phenotypes are from original isolates; all other assays, enzyme analysis, genotyping, and animal work were done with plaque-purified homogeneous TK-deficient populations.
‡ Level of thymidine kinase (TK) activity is result of at least two determinations and expressed as percentage of activity in control strain. § Genotype 0C denotes single-base deletion within C homopolymer (5 cytosines instead of 6), which yields truncated protein of 263 aa. Genotype /G (G homopolymer) has 8 guanines vs. 7 (as in wild type) and yields truncated TK protein of Ç229 aa.
x Plaque-forming units of virus required to kill 50% of mice inoculated intracerebrally. Ø [12] . ** Control viruses of known virulence.
for 4 h; results are expressed as lytic units/10 6 PBMC [23, 24] . Tissue Kit (Qiagen, Hilden, Germany) following the manufacturer's instructions. The TK of these isolates was PCR-amplified with Quadruplicate proliferation assays used 10 5 PBMC/well and 0.4 mg/mL phytohemagglutinin (Murex Diagnostics, Norcross, GA) designed primers based on the DNA sequence of the HSV-2 strain 333 TK gene (GenBank accession no. M29943). Tandem PCR or UV-inactivated cell-associated HSV strain 333 or wild type varicella zoster virus prepared as described [23, 25] . After 5 days, with the use of an upstream biotinylated primer in one reaction and a downstream biotinylated primer in the other (Oligos Etc., wells were pulsed with 1 mCi of [ 3 H]thymidine and 18 h later were harvested and analyzed by liquid scintillation; results are Wilsonville, OR) allowed for strand-specific separation using streptavidin-coated magnetic beads following the manufacturer's expressed as D counts per minute (cpm) (mean cpm mitogen or antigen 0 mean cpm for mock-infected fibroblasts). Limiting instructions (Dynal, Oslo). The PCR consisted of 300 ng of DNA, 11 Thermopol buffer (10 mM Tris-HCl, pH 8.8, at 25ЊC, 10 mM dilution assays for HSV-2 proliferative and CD8 cytotoxic T lymphocyte precursor (pCTL) responses to HSV-2 antigen were done [NH 4 ] 2 SO 4 , 2 mM MgSO 4 , 0.1% Triton X-100), 0.5 mM MgSO 4 , 250 mM dNTPs, including the use of 7-deaza-2-deoxy-GTP in a as described [26, 27] and analyzed by x 2 minimization for estimation of precursor frequency [28] , with results rounded to the nearest 3:1 ratio to dGTP for sequencing high-G:C-content DNA [31], 0.5 mM upstream and downstream primers, and 0.5 U of Vent DNA 100.
Virulence assay. Intracerebral inoculation of young mice propolymerase (New England BioLabs, Beverly, MA). PCR products were analyzed by 1% agarose gel electrophoresis, and a band vides a very sensitive system for determining virulence of HSV isolates. In general, isolates that have lost their TK activity do not Ç1.56 kb in length, the viral TK, with 90% of the TK promoter, was purified with the Wizard PCR Preps DNA Purification System cause mortality, whereas TK-positive isolates will kill mice with as few as 1-10 pfu. Five of the HSV isolates were inoculated (Promega, Madison, WI). Sequencing analysis. Sequencing was done at the Glaxo Wellinto the right cerebral hemisphere with 0.03 mL of four dilutions containing 1-10,000 pfu. A group of 10 BALB/c mice (3 weeks come Automated Fluorescent DNA Sequencing Facility. The HSV-TK solid-phase single-stranded DNA templates were submitted with old) was inoculated with each concentration and checked for mortality for 21 days. At this time, LD 50 values were calculated by 3.2 pmol of sequence primer and DMSO, for a final concentration of 5% in the sequence reaction. Twelve oligonucleotide primers, use of a computer program (Dose Effect Analysis; Elsevier Biosoft, Cambridge, UK), and plaque-forming unit/LD 50 ratios were deterdesigned on the DNA sequence of HSV-2 strain 333 TK gene, were used to sequence both strands. The fluorescent sequencing chemistry mined [29, 30] . Titers of the virus pools were determined by plaque assay in primary rabbit kidney cells. All animals were anesthetized used was Dye Terminator Cycle Sequencing with AmpliTaq DNA Polymerase, FS (Applied Biosystems, Foster City, CA), and manufacwith a mixture of ketamine-rompun before virus inoculation.
DNA purification and PCR. Vero cells were infected with each turer's protocols were followed. Sequencing was done on a DNA sequencer (model 373; Applied Biosystems) using ABI Sequence of the 6 clinical isolates and the 2 isolates recovered from infected mouse brain homogenates (14847 and 14848). HSV-specific whole The TK from the 6 original isolates recovered from the patient sera with HSV-1 and HSV-2 antigens showed a normal patient was sequenced by PCR and showed two genotypes pattern of reactivity, with multiple HSV proteins indicative of (table 1) . A single-base deletion within a homopolymer of six HSV-2 but not HSV-1 infection. To assess cellular immunity, cytosines (C homopolymer) was found in 3 of the isolates assays of HSV-specific proliferative and CD8 pCTL responses and occurred in isolates 14847 and 14848 on repeated testing, and NK cell function were performed. Proliferative response resulting in a truncated protein of Ç263 aa (wild type Å 376 by PBMC for HSV-2 antigen was 34,748 cpm. This is comparaaa). The other 3 isolates showed insertion mutations within the ble to values from 10 HIV-seronegative HSV-2 -seropositive guanine (G) homopolymer (eight guanines instead of seven), female patients with symptomatic genital HSV-2 (median D yielding a truncated TK protein of Ç229 aa (wild type Å 376 cpm, 23,526; range, 14,678 -39,656). Lymphoproliferative reaa) [32] . Despite the differences in virulence, the 2 isolates sponses to phytohemagglutinin (D cpm, 61,236) and varicellarecovered from the mice inoculated intracerebrally (14847 and zoster virus antigen (D cpm, 21,500) were also intact. Limiting 14848) showed identical genotypes to each other (as well as dilution assay for proliferative responses gave an estimated to the original isolates tested), with the same single-base deleprecursor frequency of 1/1800 (95% confidence range, 1/1400 -tion in the C homopolymer. However, although the DNA se-1/2200). The precursor frequencies for the same (n Å 10) quence for both of these isolates was identical for the TK and control group (median, 1/3346; range, 1/961 -1/11,904) and 90% of the TK promoter, the possibility of mutations in other previously healthy HSV-2 -seropositive controls were similar loci of these isolates cannot be excluded. [26] . The frequency of HSV-specific CD8 pCTL was 1/9000 (95% confidence range, 1/7000 -1/12,000). NK cell assay using Discussion K562 target cells showed that PBMC contained 20.7 lytic units/ 10 7 PBMC; the percentage of specific release was 24.3 at an This is the first reported case of persistent, nonhealing vulvar effector-to-target ratio of 100:1. Values for NK assay from 4 lesions in an immunocompetent patient due to an acyclovirhealthy persons were 19, 63, 87, and 130 lytic units/10 7 PBMC resistant, TK-deficient HSV-2 infection. Despite therapeutic (Koelle DM, unpublished data).
trials with long-term high-dose acyclovir, oral valacyclovir, Virologic studies. Phenotypic characterization of multiple and topical trifluorothymidine, vulvar erosions did not heal HSV isolates by plaque autoradiography showed that all isountil topical foscarnet cream was applied. In addition, the use of lates tested were predominantly TK-deficient. These isolates foscarnet cream has resulted in a durable remission of disease. were plaque-purified to homogeneity, and their TK activity was Chronic or recurrent vulvar erosions may be due to a variety undetectable by both TK assay and plaque autoradiographic of diseases, including HSV infection. A noninfectious primary methods (table 1) .
vulvar dermatosis was initially considered in our patient, possiFive serial patient isolates were inoculated intracerebrally bly acting as a nidus for frequently recurring HSV-2 infection. into mice to determine if their virulence had been attenuated.
Potential skin disorders included erosive lichen planus, pemphiTwo HSV isolates of known virulence were included as congus vulgaris, cicatricial or bullous pemphigoid localized to trols. The positive control was HSV-2, MS strain, and the the vulva, bullous lupus erythematosus (rarely reported to be negative control was an HSV-1 SR 6008 in which the TK localized to the external genitalia), and Behcet's syndrome, region had been deleted. The number of plaque-forming units which may produce recurrent ulcers in the genitalia and ororequired to kill 50% of mice inoculated with each of the isolates pharynx [33] . However, the lack of other mucocutaneous findis shown in table 1. Four of the five viruses tested that were ings and systemic symptoms of collagen vascular disease did TK-deficient had retained the capacity to kill mice. In particunot support a primary autoimmune bullous disorder or underlylar, virus isolate 14847 was similar to the TK-positive control ing lupus erythematosus. Likewise, direct immunofluorescence in that 10 -50 pfu were lethal. Virus isolate 14848 failed to testing was negative on 3 serial vulvar biopsies and would be kill any mice, even when 5 1 10 3 pfu were inoculated. Because expected to be positive in autoimmune bullous diseases and of this unexpected finding, a second series of samples from the lupus erythematosus. In addition, erosive vulvar lichen planus same isolates were inoculated into mice with virtually identical should respond to prolonged courses of topical or systemic results. The results shown in table 1 are the average of both steroids, and our patient showed no overall improvement after experiments. To determine the phenotype and genotype of these 6 months of consecutive topical and systemic corticosteroids. viruses (both before and after replication in the mouse), brains Chronic severe infection due to acyclovir-resistant HSV inwere harvested from mice inoculated with 14847 and 14848.
fection has been well documented in severely immunocomTissue homogenates were prepared and retested for TK phenopromised patients and in those with AIDS. Clinically significant type and sequenced. Both virus isolates recovered from mouse acyclovir-resistant HSV disease has occurred in immunosupbrain were still TK-deficient and had the same sequence as the pressed transplant recipients, cancer patients, and HIV-infected persons [2, 3, 34, 35] . On the other hand, acyclovir resistance virus that was injected into the mice. Furthermore, isolate / 9d41$$mr21 01-21-98 18:28:24 jinfa UC: J Infect in immunocompetent patients has been demonstrated in vitro activity and severe herpesvirus infections have been reported [39] , our patient appeared to have intact PBMC NK activity. without significant clinical correlation [3] . Prolonged, self-limited infections may occur in the setting of acyclovir resistance,
The frequency of HSV-specific CD8 pCTL was within the range observed for 10 immunocompetent patients with a history but severe disease with nonhealing lesions is uncommon in healthy patients [2, 3, 17, 36] . of genital herpes [28] . The data suggest that neither an HSVspecific nor a generalized immunodeficiency state contributed The patient described herein is unique in that a TK-deficient HSV infection has apparently emerged after initial improveto the development of persistent acyclovir-resistant HSV infection. ment during acyclovir treatment, producing significant morbidity in an immunocompetent heterosexual person. The acyclovirMultiple therapeutic modalities were used in this patient to evoke healing. TFT is a nucleoside analogue whose activity is resistant HSV-2 isolates recovered from this patient were extremely difficult to characterize in the phenotypic assays and not dependent on phosphorylation by the virus-specific TK [40] , and both in vitro susceptibility of acyclovir-resistant HSV may demonstrate the limits these assays have in detecting low levels of TK activity [37] . While the isolates tested were strains [41] and clinical success with its topical application for treatment of AIDS patients with acyclovir-resistant mucocutaplaque-purified three times to homogenous populations before the enzyme analysis and animal studies were done, the influneous HSV infection have been described [42 -44] . However, this modality was unsuccessful in our patient, who showed ence of undetectable low levels of TK-positive virus cannot be completely excluded in this patient.
persistent culture-positive HSV-2 infection throughout TFT therapy. Valacyclovir is a valine ester prodrug of acyclovir that Animal models are extremely efficient at detecting low levels of virulence [5, 38] , as demonstrated by our studies in which yields plasma levels of acyclovir similar to those seen with intravenous acyclovir [45] . Despite prior reports of success 4 of 5 isolates were virulent, although at a reduced level compared with virulence of the TK-positive MS strain. Further with use of continuous-infusion acyclovir for treatment of acyclovir-resistant infection in patients with AIDS [46 -49] , as evidence supporting the fact that these virus pools were homogenous populations of TK-deficient HSV is that the virus isolated well as documentation of high serum levels of acyclovir with both low and high doses of the drug, valacyclovir was unsucfrom the brains of mice that died from infection had the same phenotype and genotype as the original infecting virus. This is cessful in evoking healing of vulvar erosions in our patient. Like TFT, foscarnet (trisodium phosphonoformate) does not in contrast to an isolate recently described by Sasadeusz and Sacks [37] , who inoculated a TK-deficient virus into mice and require viral TK phosphorylation for its antiviral activity [50] . Foscarnet is a potent inhibitor of HSV DNA polymerase and recovered a TK-positive virus from animals that died, suggesting either selection of a TK-positive virus from a heterogehas been shown to effectively treat acyclovir-resistant infection in immunocompromised persons when administered parenterneous mixture or complementation between the TK-deficient isolate and wild type virus. However, it is important to reiterate ally [51 -53] . However, its systemic use is limited by potentially severe toxicity, including renal impairment, granulocytothat of the 5 TK-deficient isolates from our patient that were tested in mice, only 1 failed to kill the animals.
penia, and metabolic disturbances (particularly in phosphate, calcium, and magnesium levels). Phenotyping and sequencing isolates before and after mouse inoculation demonstrated TK deficiency and identical TK deleWhile foscarnet cream has shown no significant benefit over oral acyclovir in healthy, immunocompetent patients with retion mutations. The C and G homopolymer loci, in which the mutations in our isolates were localized, have previously been current genital herpes [54 -56] , it may have a singular role in certain subsets of patients, such as those with acyclovir-resisshown to be sites of high mutational activity and appear to be responsible for 40% -50% of acyclovir-resistant HSV isolates tant disease. A recently completed pilot study of foscarnet cream in AIDS patients with acyclovir-resistant HSV-2 infec- [32] . Although the entire coding region of the TK protein in our patient's isolates was sequenced, including 90% of the tion [57] showed marked reduction in pain in 50% of patients and complete healing of HSV lesions in 45% of 20 patients. promoter region and 41% of the 3 untranslated region, we cannot exclude the possibility that some other mutational Our patient showed a dramatic and lasting response to topical foscarnet cream since it was initiated in June 1995, experiencchanges responsible for neurovirulence may have occurred in regions that were not sequenced.
ing rapid symptomatic relief and complete resolution of vulvar burning, itch, and pain within 1 day of foscarnet application, We intensively evaluated the immune status of our patient. No evidence of HIV infection or collagen vascular disease was and becoming free of herpetic lesions for the first time since July 1993 or earlier. present. She appeared to have a normal immune response to HSV-2. The profile of antibody reactivity observed with HSVOur patient is the first healthy and otherwise immunocompetent person in whom acyclovir-resistant, TK-deficient HSV 2 immunoblot assay using patient sera was typical for longstanding HSV-2 infection [22] . Results of bulk lymphoprolifercaused chronic and recurrent, nonhealing vulvar erosions for a period of ú3 years. Implications regarding similar infections ation and limiting dilution proliferation assays were within the range of values obtained for immunocompetent patients with in otherwise immunocompetent persons will require observation over time. recurrent genital HSV-2. Although rare patients with low NK / 9d41$$mr21 01-21-98 18:28:24 jinfa UC: J Infect
